EyePoint, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EYPT in the last 7 days.
No SEC Form 4 filings for $EYPT in the last 30 days.
See all $EYPT insider activity →Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
EyePoint, Inc. (EYPT) granted stock options for 3,000 shares to a new employee, exercisable at $3.66 per share. The options vest over four years. EyePoint is developing DURAVYU for retinal diseases, with Phase 3 trials ongoing. Topline data for wet AMD was disclosed in August 2026, and further data is expected in Q4 2026.
Recent EYPT coverage spans market movers, financial news and sector analysis.
Price decline reflects sector‑wide concerns over competitive landscape.
Phase III readout could support an NDA for DURAVYU.
Minor dilution risk; limited immediate price impact.
The sharp intraday decline suggests short‑term pressure; no clear catalyst beyond market flow data.
Analyst reaffirmation with higher target could lift the stock modestly.
AlphAI scores every news story that mentions EYPT with an AI model for sentiment and relevance, and aggregates insider trades from EyePoint, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
2 min readArcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
2 min readEyePoint, Inc. (EYPT) granted stock options for 3,000 shares to a new employee, exercisable at $3.66 per share. The options vest over four years. EyePoint is developing DURAVYU for retinal diseases, with Phase 3 trials ongoing. Topline data for wet AMD was disclosed in August 2026, and further data is expected in Q4 2026.
1 min readEypt stock (EYPT) fell 12% today with $8.78M in trading volume. Insiders traded shares twice in 6 months, with 1 purchase and 1 sale. 89 hedge funds added shares, while 96 reduced positions. Analysts' median price target is $56.0.
1 min readAnalysts reiterated Buy ratings for BridgeBio Pharma (BBIO) with a $120 price target, EyePoint Pharmaceuticals (EYPT) with a $17 target, and Abbott Laboratories (ABT) with a $125 target. BBIO and ABT have Strong Buy consensus, while EYPT has Moderate Buy.
2 min readEyePoint posted an updated investor presentation showing LUGANO Phase 3 DURAVYU topline results. While the full dataset did not achieve non-inferiority (NI) due to an asymmetric cohort, ad hoc analysis showed NI in BCVA. DURAVYU reduced treatment burden by 42% and had a favorable safety profile. EyePoint plans to file an NDA for wet AMD in H1 2027, pending positive LUCIA results and pre-NDA FDA engagement in Q4 2026.
1 min readEvercore initiates Lumentum (LITE) at Outperform with a $1,100 target, citing strong demand for Indium Phosphide lasers in AI. Jefferies upgrades Sempra Energy (SRE) to Buy, seeing undervaluation. TD Cowen downgrades Eyepoint (EYPT) to Hold, citing poor trial results. Truist downgrades Covista (CVSA) to Hold, citing valuation concerns. Baird upgrades Sonida Senior Living (SNDA) to Outperform, citing demographic trends.
3 min readMajor indices closed lower Tuesday due to war tensions and rising oil prices. The 30-year Treasury yield hit 5.27%, its highest since 2007, while Brent Crude surged 5% to $95. Analysts initiated coverage on Ally Financial (Strong Buy, $55 target) and GLOBAL FOUNDRIES (Buy, $60 target), among others.
3 min readUS stocks are mixed, with chipmakers and AI-infrastructure stocks rising, while software companies decline. Treasury Secretary Bessent announced upcoming economic measures against Iran. S&P 500 is tracking for 32% Q2 earnings growth, with 85% of companies beating estimates. Marvell (MRVL) and Sandisk (SNDK) lead gains, while Datadog (DDOG) and Salesforce (CRM) lead losses. Astera Labs (ALAB) and Onto Innovation (ONTO) received upgrades, while EyePoint (EYPT) plunged after a failed trial.
6 min readStock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
6 min read
